News
Catch up on our latest press releases, corporate updates and announcements.
Press Releases
ALL
2023
2022
Structure Therapeutics CEO Raymond Stevens Named to PharmaVoice 100
/in 2022, Press Releases/by GrahamStructure Therapeutics Extends Financing, Advances Diabetes and Obesity Clinical Program and Changes Name from ShouTi
/in 2022, Press Releases/by GrahamShouTi Introduces Basecamp Bio as a Wholly Owned Subsidiary to Expand Pipeline and Partnerships
/in 2022, Press Releases/by GrahamShouTi Strengthens Board with Appointment of Daniel G. Welch as Chairman
/in 2022, Press Releases/by Graham2021
ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
/in 2021, Press Releases/by GrahamIn the Media
BioSpace: ShouTi’s Rationally Designed Small Molecules are Challenging Biologics and Peptides
https://www.biospace.com/article/shouti-s-rationally-designe…
Wall Street Journal: VC Daily: ShouTi Lands $100 Million to Develop Pills for Chronic Diseases
https://www.wsj.com/articles/vc-daily-shouti-lands-100-milli…
FierceBiotech: Receptos founder returns with ShouTi and $100M for oral drugs to treat chronic diseases
https://www.fiercebiotech.com/biotech/receptos-founder-retur…
Endpoints News: A new Schrödinger-backed startup emerges from the scientist who mapped the first human GPCR
https://endpts.com/a-new-schrodinger-backed-startup-emerges-…
Structure Based Discovery and Anti-fibrotic Activity of Novel Antagonists of Lysophosphatidic Acid Receptor 1 (LPAR1) (Presented at ATS 2023)
/in Press Releases/by JustinA First-in-Human Single/Multiple Ascending Dose Study of ANPA-0073, a Novel Small Molecule G-protein Biased Apelin Receptor Agonist, in Healthy Volunteers (Presented at ATS 2023)
/in Press Releases/by JustinDiscovery of G-protein Biased Small Molecule APJ Agonist for Pulmonary Disease (Presented at ATS 2023)
/in Press Releases/by JustinStructure Therapeutics Appoints Industry Leaders Eric Dobmeier and Joanne Waldstreicher to its Board of Directors
/in 2023, Press Releases/by GrahamStructure Therapeutics CEO Raymond Stevens Named to PharmaVoice 100
/in 2022, Press Releases/by GrahamStructure Therapeutics Extends Financing, Advances Diabetes and Obesity Clinical Program and Changes Name from ShouTi
/in 2022, Press Releases/by GrahamShouTi Appoints Sharon Tetlow to Board of Directors
/in 2022, Press Releases/by GrahamShouTi Introduces Basecamp Bio as a Wholly Owned Subsidiary to Expand Pipeline and Partnerships
/in 2022, Press Releases/by GrahamShouTi Strengthens Board with Appointment of Daniel G. Welch as Chairman
/in 2022, Press Releases/by GrahamShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
/in 2021, Press Releases/by Graham